• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Topical photosensitizers, PDT preferred for AK, BCC tx

When treating actinic keratoses (AK) or basal cell carcinoma (BCC), using a topical photosensitizer like methyl aminolevulinate for photodynamic therapy is less invasive and provides excellent cosmetic results, Rolf-Markus Szeimies, M.D., Ph.D., said yesterday in his presentation on "Methyl Aminolevulinate for Photodynamic Therapy."

When treating actinic keratoses (AK) or basal cell carcinoma (BCC), using a topical photosensitizer like methyl aminolevulinate for photodynamic therapy is less invasive and provides excellent cosmetic results, Rolf-Markus Szeimies, M.D., Ph.D., said yesterday in his presentation on "Methyl Aminolevulinate for Photodynamic Therapy."

He added that cure rates for both AK and BCC lesions are close to those achieved by other therapeutic modalities.

MAL was approved by the U.S. Food and Drug Administration in July 2004 for use in treating AK.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this program
1 KOL is featured in this program
1 KOL is featured in this program
Ted Lain, MD, MBA, FAAD, is featured in this series.
Ted Lain, MD, MBA, FAAD, is featured in this series.
Ted Lain, MD, MBA, FAAD, is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.